Novo Nordisk lifts 2025 outlook despite Wegovy pill miss

Novo Nordisk Wegovy CagriSema Q2 results guidance

Novo Nordisk reported second‑quarter 2026 results with adjusted sales of 78.49 billion Danish kroner, up 7 % year‑on‑year, and adjusted operating profit of 33.389 billion kroner, up 11 %. The oral version of its weight‑loss drug Wegovy generated 3.2 billion kroner in sales, slightly below analysts’ expectation of 3.3 billion kroner, while the injectable Wegovy contributed 19.48 billion kroner.

The company raised its full‑year 2025/2026 guidance, stating that sales and operating profit are now expected to decline by no more than 6 % at constant exchange rates, an improvement from the prior forecast of a 4‑12 % decline. At the same time, a late‑stage trial of the next‑generation obesity drug CagriSema showed weight‑loss results non‑inferior to tirzepatide but a smaller HbA1c reduction (1.9 % versus 2.2 %).

Investors reacted negatively: Novo Nordisk shares fell about 5‑6 % after the earnings release, and the ADR dropped nearly 6 % on the day. The company also declared a dividend of 0.5786 DKK per share.

Entities

CagriSema · Eli Lilly · Mike Doustdar · Novo Nordisk · Novo Nordisk A/S · Ozempic · Wegovy (oral)

Claims

What the coverage asserts, and how many sources carry each claim.

[DISPUTED] Novo Nordisk's Q2 adjusted sales were 78.49 billion Danish kroner, up 7 % YoY. bbc.bm · www.eeo.com.cn · finance.technews.tw · www.fool.com · www.kapitalmarktexperten.de · +2 more
[● 2 SOURCES] Novo Nordisk raised its full‑year 2025/2026 guidance, expecting sales and operating profit to decline by no more than 6% at constant exchange rates. econotimes.com · bbc.bm
[DISPUTED] Novo Nordisk shares fell about 5‑6 % after the earnings release. econotimes.com · bbc.bm · www.kapitalmarktexperten.de · www.fool.com · www.businesstimes.com.sg · +2 more
[● 8 SOURCES] Injectable Wegovy Q2 revenue was 19.48 billion Danish kroner. econotimes.com · bbc.bm · www.kapitalmarktexperten.de · www.fool.com · www.businesstimes.com.sg · +2 more
[● 2 SOURCES] Wegovy oral has been prescribed over five million times in the US, with weekly prescriptions exceeding 265 000. www.eeo.com.cn · finance.technews.tw
[● 8 SOURCES] Adjusted operating profit was 33.389 billion Danish kroner, up 11 % YoY. www.eeo.com.cn · finance.technews.tw · bbc.bm · econotimes.com · www.fool.com · +2 more
[● 3 SOURCES] CagriSema trial showed weight‑loss non‑inferior to tirzepatide, with HbA1c reduction of 1.9 % versus 2.2 % for tirzepatide. econotimes.com · bbc.bm · www.businesstimes.com.sg
[● 8 SOURCES] Oral Wegovy Q2 sales were 3.2 billion Danish kroner, below analysts' expectation of 3.3 billion kroner. econotimes.com · bbc.bm · www.fool.com · www.kapitalmarktexperten.de · www.businesstimes.com.sg · +2 more
[● 2 SOURCES] Novo Nordisk raised its full‑year 2025/2026 guidance to a decline of no more than 6 % at constant exchange rates. econotimes.com · bbc.bm
[● 5 SOURCES] Oral Wegovy sales in Q2 were 3.2 billion Danish kroner, slightly below analysts’ expectation of 3.3 billion kroner. bbc.bm · www.kapitalmarktexperten.de · www.businesstimes.com.sg · econotimes.com · finance.technews.tw
[DISPUTED] Novo Nordisk Q2 2026 adjusted sales were 78.49 billion Danish kroner, up 7 % YoY. bbc.bm · econotimes.com · www.eeo.com.cn
[● 2 SOURCES] CEO Mike Doustdar said Novo will accelerate R&D and pursue bolt‑on acquisitions. bbc.bm · econotimes.com